BioMarin Pharmaceutical (BMRN) Tmuɣli n wazal
Ṛṛbem n lḥedd$60.22Yettwalemmaḍ 25 Sep 2026 19:59 UTC
Beddel-1.84%
Asnulfu n AI: BMRN
AI tessawal ɣef timaqsiṭ n wazal i wass n tnekkit d-iteddun, taggara n yimal akked taggara n waggʷas. Asnifel yettwamḍen seg wazal aneggaru. Aya d tinineḍ n tḥisabt, ma tga ara timsisi n usihel.
Asref n 6 isggʷasn ineggura
Premium tessaɣ-d iswiyat n tɣara n AI i wass, amalas d waggʷas n yiwen i uḍris-a akk d yisɣunan niḍen.
Serreḥ Premium🔒 Tazmilt n usenfar
Amezruy n tmuɣliyin — akk tmuɣliyin n zik akked wazal n tnekkit — d akcum n Premium.
Serreḥ PremiumƔef tneɣlaft-a
BioMarin Pharmaceutical Inc. develops and markets therapeutic enzyme products. The company has applied its proprietary enzyme technology to develop treatments for lysosomal storage diseases and serious burns. BioMarin Pharmaceutical also provides analytical and diagnostic products and services in the field of carbohydrate biology.
